Groundbreaking immunotherapy drug teplizumab licensed in UK for delaying early stages of type 1 diabetes
This is a milestone moment and the beginning of a new era for type 1 diabetes treatment. Teplizumab tackles the root cause of type 1 diabetes – the immune system attack on insulin-making beta cells. By slowing this attack, teplizumab can protect beta cells and hold off a type 1 diabetes...
Unfortunately it does come with a few caveats.
- This is only for those in early stages (so not me or @Blackpill Monk)
- It's not a cure (yet, but you know what they say, there will be one in 5 years™)
